What is Tissium?
Headquartered in Paris, France, Tissium operates at the intersection of material science and clinical surgery. The company specializes in the development and manufacturing of synthetic, polymer-based solutions designed for tissue repair, reconstruction, and sealing. By leveraging a unique biopolymer platform, Tissium provides surgeons with versatile tools for nerve repair, wound closure, and tissue reinforcement. Its market position is defined by a focus on high-precision medical devices that improve patient outcomes while streamlining surgical workflows. As a privately-owned entity, Tissium has successfully navigated the complexities of the medtech landscape, evolving from early-stage development to a mature enterprise capable of delivering transformative healthcare technologies.
How much funding has Tissium raised?
Tissium has raised a total of $259.5M across 6 funding rounds:
Series A
$27.4M
Series B
$42.8M
Debt
$8.2M
Series C
$59.1M
Series D
$53.8M
Other Financing Round
$68.1M
Series A (2016): $27.5M with participation from Cr�dit Mutuel Innovation, Karista, Omnes Venture Capital, and Sofinnova Partners
Series B (2020): $42.8M led by Bpifrance, Cap Décisif Management, Sofinnova Partners, European Investment Fund, M&L Investments, BNP Paribas Développement, CM-CIC Innovation, Omnes Capital, and ValQuest Partners
Debt (2020): $8.2M supported by Bpifrance, BNP Paribas, and CM-CIC Securities
Series C (2021): $59.1M featuring Sofinnova Partners and Cathay Health
Series D (2023): $53.8M backed by Cathay Capital, Sofinnova Partners, and Mérieux Equity Partners
Other Financing Round (2026): $68.1M with participation from European Investment Bank
Key Investors in Tissium
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
European Investment Bank
The European Union's nonprofit long-term lending institution, focused on supporting innovation and infrastructure projects across the continent.
Cathay Capital
An international private equity firm specializing in cross-border investments that facilitate the expansion of middle-market enterprises across multiple continents.
What's next for Tissium?
With the successful completion of this major strategic investment, Tissium is well-positioned to scale its manufacturing capabilities and expand its international footprint. The capital will likely be deployed to advance the clinical validation of its pipeline and support the regulatory pathways required for broader market adoption. By maintaining its focus on deeptech innovation and strategic partnerships, the company is poised to solidify its leadership in the tissue-sealing market. Future growth will likely center on deepening its presence in key markets across Europe and North America, ensuring that its biopolymer solutions become a standard of care in modern surgical environments.
See full Tissium company page
